UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40959 ROTH CH ACQUISITION CO. (Exact name of registrant as specified in its charter) | Cayman Islands | 98-1601095 | | --- | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40477 SRx Health Solutions Inc. (Exact name of registrant as specified in its charter) Delaware 83-4284557 (State or other juri ...

Product Development - Adimune's first product candidate, ADI-100, targets glutamic acid decarboxylase (GAD) implicated in type-1 diabetes and autoimmune diseases, with successful preclinical tests [313]. - Preclinical studies for ADI-100 demonstrated durable tolerance restoration over a 10-month duration, with no drug toxicity or antibody formation observed [314]. - Adimune plans to initiate human trials for Stiff Person Syndrome in 2025, with an expected enrollment of 10-20 patients, pending regulatory approvals [317]. - Pearsanta is developing two product candidates for cancer screening, including potential tests for prostate cancer and endometriosis [326]. - The Mitomic® Prostate Test (MPT™) is in development to quantify the 3.4kb mitochondrial DNA deletion, potentially aiding in the identification of clinically significant prostate cancer in men with PSA levels below 10 ng/ml [339]. - The Mitomic Endometriosis Test (MET™) aims to quantify mitochondrial DNA deletions associated with endometriosis, a condition affecting approximately 10% of women [340]. - AditxtScore technology provides a comprehensive immune profile, detecting responses to various agents, with rapid assays completed in approximately 3-16 hours [328]. - The Mitomic® Technology platform aims to detect mutations in mitochondrial DNA, potentially identifying diseases before clinical presentation [336]. - The Mitomic® Technology has discovered numerous biomarker targets, with ongoing development of robust assays and new products [337]. - Pearsanta's laboratory facility in Richmond, VA, is equipped for rapid development of innovative tests, ensuring high sensitivity and specificity [334]. Financial Performance - For the three months ended March 31, 2025, the company generated revenue of $1,018, a significant decrease from $79,680 in the same period in 2024, attributed to reduced AditxtScore orders due to decreased COVID testing [356]. - The company incurred a loss from operations of $5,608,115 for the three months ended March 31, 2025, compared to a loss of $11,535,646 in the same period in 2024, reflecting a decrease in general and administrative expenses [357][358]. - As of March 31, 2025, the company had an accumulated deficit of $173,804,878 and working capital of $(13,959,063) [360]. - The company has not generated significant revenues to date and requires substantial additional capital to fund operations and clinical studies [353]. - The company raised approximately $9 million from a private placement in September 2023, which was used for outstanding obligations and working capital [363]. - The company is currently over 90 days past due on several vendor obligations, raising concerns about its ability to continue as a going concern beyond one year [353]. - The company requires significant additional capital to fund operations and clinical trials, potentially through selling common stock, preferred stock, or convertible debt securities [369]. - Future financing will depend on market conditions and the progress of the clinical development program, with current cash reserves expected to be sufficient for the foreseeable future [370]. - As of March 31, 2025, the company's total contractual obligations amount to $960,322, with $536,392 due in 2025 and $423,930 in 2026 [372]. Strategic Initiatives - The company entered into an Asset Purchase Agreement to acquire a 50% ownership interest in G Response Aid FZE for $24.5 million, which includes the forgiveness of a $14.5 million loan and approximately $10 million in cash [346]. - The company anticipates that the development of the acquired Adductomics Technology will provide insights into DNA damage and cancer risk over the next two to three years [344]. - The company intends to rely on exemptions provided by the JOBS Act, including delaying the adoption of certain accounting standards until they apply to private companies [377]. - The company is classified as an "emerging growth company" and will remain so until it meets specific revenue or debt thresholds [377]. - The company is evaluating the benefits of relying on reduced reporting requirements under the JOBS Act [377]. - Recent developments and material changes are documented in the accompanying condensed consolidated financial statements [380]. - The company is not required to provide quantitative and qualitative disclosures about market risk as it is classified as a "smaller reporting company" [381].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) SMART POWERR CORP. (Exact name of registrant as specified in its charter) Nevada 90-0093373 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4/F, Tower C Rong Cheng Yun Gu Building Keji 3rd Road Yanta District, Xi An City Shaan Xi Province, China 710075 (Address of principal executive offices) (Zip Code) (011) 86-29-8765-1098 (Registrant's telephone number, includin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission File Number 001-37420 SERITAGE GROWTH PROPERTIES (Exact name of registrant as specified in its charter) Maryland 38-3976287 (State of Incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) _______________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to Commission file number: 001-42385 BOLD EAGLE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to Commission file number: 001-42385 BOLD EAGLE ACQUISITION CORP. (Address of principal executive offices) (Zip Code) Registrant's telephone number, including ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-42301 FRONTVIEW REIT, INC. (Exact name of registrant as specified in its charter) Maryland 93-2133671 (State or other jurisdiction of incorporation or organization) 3131 McKinn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-37899 SCWORX CORP. (Exact name of registrant as specified in its charter) Delaware 47-5412331 (State or other jurisd ...